Stryker Corp. stock extends slide as analysts trim targets but keep buy ratings
Published on 09/11/2026 at 22:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Stryker Corp. stock (ISIN US8636671013) is trading close to its 52-week low, with shares around USD 270.01 on the NYSE as of September 10, 2026, after a sharp multi-session decline that has erased billions in market value for the medical technology group.
Stock under pressure but consensus stays positive
According to an analysis on September 11, 2026, Stryker stock has fallen 18 percent over its last eight trading sessions, dropping from roughly USD 330 to a close near USD 270.01 and cutting about USD 23,000,000,000 from the company’s market capitalization, which now stands at around USD 104,000,000,000.Trefis The move has taken the shares to their 52-week low of USD 270.01, while the 52-week high is reported around USD 392.55 in recent coverage.MarketBeat
Despite the sell-off, analysts continue to rate Stryker positively. Data compiled on September 11, 2026, show a mean consensus rating of Buy from 28 analysts, with an average price target of USD 376.28 compared with a last close price of USD 270.01, implying upside of about 39.36 percent if the consensus is reached.MarketScreener Separate coverage on September 11, 2026, notes that the average target price stands at USD 380.40 and highlights that several houses have recently reduced individual targets while keeping ratings in the Buy range.MarketBeat
Citi trims price target but keeps buy view
An important catalyst for Stryker Corp. stock on September 11, 2026, is an updated view from Citi. According to a rating overview on that date, Citi analyst Joanne Wuensch maintains a Buy rating on Stryker but lowers her target price from USD 399 to USD 360, reflecting a more cautious stance after the recent drawdown and operational concerns.Futunn News Even after this cut, Citi’s new target still offers notable potential compared with the USD 270.01 area where the stock recently traded, underscoring that the analyst continues to see long-term growth drivers for the company.
Other analyst reports summarized on September 11, 2026, indicate that several institutions have reduced their price targets in recent weeks, with one source mentioning that a prior target of USD 418 was lowered to USD 348, while the average target of roughly USD 380 remains well above the current quotation.MarketBeat For investors, these moves show that the analyst community is reacting to recent risks, but the underlying ratings continue to support a constructive view on Stryker’s medium-term prospects.
Recent fundamentals and dividend support
Fundamentally, Stryker remains profitable and continues to provide guidance for the current fiscal year. A recent institutional-report summary dated September 11, 2026, notes that the company has maintained fiscal 2026 earnings-per-share guidance in a range of USD 14.95 to USD 15.10, signaling management’s confidence in achieving double-digit earnings despite near-term share price volatility.MarketBeat Compared with historical levels, this guidance points to continued earnings growth for the group’s mix of orthopedics, surgical, neurotechnology and spine products.
Income investors also benefit from an ongoing dividend stream. A market overview on September 11, 2026, shows that Stryker has declared a cash dividend of USD 0.88 per share, with an ex-dividend date of September 30, 2026.Yahoo Finance On an annualized basis, the dividend amounts to USD 3.52 per share and represents a yield of about 1.3 percent at a share price near USD 270, offering a modest income component alongside potential capital appreciation.MarketBeat
Looking at recent performance, one portal summarizing returns on September 11, 2026, reports that Stryker shares declined approximately 22 percent over the previous 30 days, falling from a close near USD 347 in mid-August to around USD 270 in early September.Tickeron That decline leaves the shares roughly 21.92 percent lower over one month and down 23.18 percent year to date, according to performance data shown for September 11, 2026.Yahoo Finance
Risk factors behind the recent downturn
The recent slide in Stryker Corp. stock has been linked in part to supply concerns and operational challenges in specific product lines. Commentary published on September 11, 2026, points to mounting supply issues that have affected deliveries of certain surgical and implant products and raised questions about near-term margin resilience.Tickeron Other coverage has underscored challenges in Stryker’s peripheral vascular and hip portfolios, with market participants keen to see how management addresses these issues in upcoming communications.Ad-hoc-News
Valuation-focused analysis on September 11, 2026, suggests that, after the correction, Stryker shares may now trade below estimated intrinsic value. One model-based review calculates a fair value around USD 311.21 per share versus a last close of USD 270.01, indicating the stock could be about 13 percent undervalued if those assumptions prove accurate.Simply Wall St For investors, the key question is whether supply and portfolio risks are transient issues or signal a longer-lasting shift in the company’s earnings trajectory.
Stock levels and trading data
Per recent consensus data, Stryker Corp. stock closed at USD 270.01 on the NYSE on September 10, 2026, marking a 1.95 percent decline for that session as the broader S&P 500 index also moved lower.Ad-hoc-News Intraday indications on September 11, 2026, placed the stock opening or trading near USD 269.98, marginally below that closing level and essentially at the 52-week low, underscoring the pressure from recent sessions.MarketBeat
While detailed intraday volume and exact market capitalization figures for September 11, 2026, are not broken out in the available snapshots, recent commentary shows that the company’s market value is around USD 104,000,000,000 at a price of roughly USD 270, highlighting Stryker’s status as a large-cap constituent of major healthcare and broad-market indices.Trefis For investors monitoring technical levels, the current price zone around USD 270.01 is notable as it aligns with the 52-week low, while consensus targets above USD 360 suggest substantial distance to what analysts consider fair value.
Key data on Stryker Corp. stock
- Company: Stryker Corp.
- ISIN: US8636671013
- Ticker: SYK
- Trading venue: NYSE
- Price (as of September 10, 2026): 270.01 USD
- Market capitalization: 104,000,000,000 USD (as of September 11, 2026)
- Sector / Industry: Health Care / Medical Technology
- Index membership: S&P 500
- Next earnings date: September 30, 2026
